Results of Shareholder Analysis
CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of December 31, 2025, revealing significant holdings by Andrew Webb with 14.10%, Christopher McConville with 9.65%, Brian Murray with 9.49%, David Lawton with 9.28%, and Zeus Dynamic Opportunities Fund with 3.67%. Following recent share issuances, neither Linista Group Inc. nor Spreadex hold a disclosable stake. The company is preparing to initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in glioblastoma patients in Q1 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 31 December 2025, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company ("Ordinary Shares").
| Shareholder | No. of Ordinary Shares | % interest in the ordinary share capital of the Company |
|---|---|---|
| Andrew Webb | 7,297,190 | 14.10% |
| Christopher McConville | 4,992,033 | 9.65% |
| Brian Murray | 4,908,700 | 9.49% |
| David Lawton | 4,802,416 | 9.28% |
| Zeus Dynamic Opportunities Fund | 1,900,000 | 3.67% |
Following the issue of the placing and retail offer shares (as announced on 10 and 15 December 2025 respectively) neither Linista Group Inc. or Spreadex hold a disclosable shareholding in the Company.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.